South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a ...

Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it ...

Celltrion, a major Korean biopharmaceutical firm, said Tuesday its fourth quarter net profit had skyrocketed from a year ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Tuesday its fourth-quarter net profit skyrocketed from a year earlier on robust sales of biosimilar medicines and the merger with its ...

In recent weeks, global markets have been grappling with geopolitical tensions and concerns over consumer spending, leading to fluctuations in major indices such as the S&P 500 and Dow Jones ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Celltrion’s strategy with its biosimilar of MSD’s Remicade (infliximab), launched in most of Europe around two years ago, was to go for two marketing authorisations and sell rights to one of ...

SEOUL, Feb. 27 (Yonhap) -- South Korean stocks started lower Thursday on lingering tariff woes despite the ...